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Background: Some malignancies are known to be associated with increased risk of herpes zoster, but little is known about how
associations between cancer and subsequent zoster risk vary by cancer site, by time since cancer diagnosis, and by age.
Methods: An age-, sex-, calendar time-, and practice-matched case–control study, nested in the broadly UK representative
Clinical Practice Research Datalink (CPRD) primary care database, was analysed using conditional logistic regression to estimate
the association between 21 of the most common specific malignancies and subsequent zoster risk. We adjusted for comorbid
conditions and other potential confounders, and investigated effect modification by age and time since malignancy diagnosis.
Results: A total of 192 081 adult zoster patients and 732 035 controls were included. Malignancy overall was positively associated
with zoster risk (adjusted OR 1.29, 95% CI 1.27–1.32), and the association was especially strong for haematological malignancies
(OR 2.46, 2.33–2.60). Among specific malignancies, there was evidence that oral, oesophageal, stomach, colorectal, lung, breast,
ovarian, prostate, kidney, bladder, and CNS cancers, as well as lymphoma, myeloma, and leukaemia were associated with
increased zoster odds (Pp0.05 in each case), but the magnitude of associations varied widely. The association was typically
strongest within 2 years of malignancy diagnosis and decreased with older age for both haematological and solid malignancies.
Conclusions: Several cancers were associated with an increased risk of zoster, particularly within the first 2 years after diagnosis
and among younger individuals. Knowledge that patients with a recent diagnosis of cancer are at high risk of zoster may
encourage initiation of antiviral therapy earlier in the course of zoster when the benefits are greater. Evaluation of whether patients
diagnosed with cancer would benefit from early zoster vaccination is warranted.
Herpes zoster (shingles) occurs when varicella zoster virus (VZV)
reactivates from its dormant state during periods of reduced cell-
mediated immunity, causing a characteristic rash and substantial pain
(Thomas and Hall, 2004), which can significantly impact on quality of
life (Drolet et al, 2010). Zoster incidence is 3–5 per 1000 person years
and 5–30% of patients develop postherpetic neuralgia (PHN; Kawai
et al, 2014). A vaccine to prevent zoster has recently become available,
but its high cost makes identifying priority groups important. Zoster
incidence is increased among females and older individuals (Thomas
and Hall, 2004; Kawai et al, 2014; Liu et al, 2015), and with many
immunosuppressed conditions (Forbes et al, 2014).
Cancer patients may experience cell-mediated immunosuppres-
sion, resulting from chemotherapy, psychological stress, or
physical trauma of surgery or radiotherapy, putting them at greater
risk of herpes zoster. We identified seven studies estimating an
association between prevalent/previous malignancy and zoster
(Heymann et al, 2008; Hata et al, 2011; Habel et al, 2013;
Weitzman et al, 2013; Forbes et al, 2014; Liu et al, 2015;
Yenikomshian et al, 2015), and all of them found a positive
association. Studies of specific malignancies and zoster are important
for informing prevention and understanding causality but have been
underpowered (Habel et al, 2013), had control groups severely
impacting on interpretability (Hata et al, 2011; Habel et al, 2013), or
analysed a limited number of specific malignancies (Heymann et al,
2008; Forbes et al, 2014) or sub-groups (Yenikomshian et al, 2015).
Only a few studies have looked at interactions with age and time
since malignancy diagnosis (Heymann et al, 2008; Habel et al,
2013; Weitzman et al, 2013; Yenikomshian et al, 2015); further
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evidence on this is needed to identify when efforts to prevent
malignancy-related zoster are likely to be most beneficial.
We undertook the present study to overcome the above-listed
limitations of existing evidence by performing well-powered
analyses investigating the associations between a range of site-
specific malignancies, some of which have not been studied
previously, and herpes zoster, in the general population, and
exploring how these associations vary by age and time since cancer
diagnosis.
MATERIALS AND METHODS
Study design. An age-, sex-, calendar time-, and practice-matched
case–control study, nested within the Clinical Practice Research
Datalink (CPRD) cohort was used. The study is based on a
previous published study of zoster risk factors (Forbes et al, 2014),
which provides further details on participant selection and variable
definitions, to supplement our description below.
Setting. Clinical Practice Research Datalink is a database of
general practice patient records covering 7% of the 98% of the UK
population registered with a general practitioner (GP). It is broadly
representative of this population in terms of age, sex, and ethnicity
(Herrett et al, 2015). It was initially set up in 1987 and contains GP
diagnoses and prescriptions, and information sent from hospitals
to GPs in response to referrals in Read code format. 58% of CPRD
participants are linked to the Hospital Episode Statistics (HES)
database, storing International Classification of Disease (ICD)
codes from hospital attendance (Herrett et al, 2015). Linkage is
only available for participants in England, but there are reported to
be no substantial differences in patient characteristics between
those that are linked to HES and those that are not (Gallagher et al,
2011). Varicella vaccination is not given in the UK, but zoster
vaccination was initiated for those aged 70 and 79 years in
September 2013.
Participants. The base study population from which the cases and
controls were selected consisted of individuals in CPRD with and
without HES linkage, in follow-up any time between 1 January
2000 and 30 August 2015,418 years, with no historical records for
diagnosed zoster or PHN before start of follow-up in the database.
To exclude the possibility that zoster vaccination influenced the
results, a sensitivity analysis was conducted restricted to zoster
cases diagnosed up to September 2013, which is the date that
vaccination was introduced in the UK.
Cases were those with an incident herpes zoster diagnosis
(ICD10 code B02, B02.0, B02.1, B02.31, B02.7, B02.8, B02.9, or
G53.0 in HES or corresponding Read codes in CPRD
(Supplementary Appendix A)) recorded in CPRD or HES after
at least 12 months of follow-up in CPRD. This 12-month criterion
was used to ensure that cases were truly incident, since zoster
coded early in follow-up might represent retrospective recording of
clinical history in the period immediately after GP registration
(Lewis et al, 2005). Patients identified through HES with zoster
diagnosis codes in the secondary diagnosis field were excluded, as
it was uncertain if this reflected incident zoster. The earliest date of
either the CPRD or HES zoster diagnosis date was used as the
index date.
Controls were sampled using incidence density sampling. They
were required to have no previous zoster diagnosis recorded at the
index date of their matched case; as with cases, controls were also
required to have at least twelve months of follow-up preceding the
index date, which would allow time for any historical zoster
episodes to be recorded by the GP.
Variables. Information on comorbidities, alcohol use, smoking,
body mass index (BMI), and GP prescription records of oral and
inhaled corticosteroids, and other immunosuppressive treatment
within three months preceding index date was obtained through
CPRD. Three months was considered a reasonable cutoff
considering the assumed duration of immunosuppressive effects
of these drugs (Forbes et al, 2014). All explanatory variables were
obtained using the closest relevant records prior to the index date
for both cases and controls, except for BMI, which could be
obtained within 1 year after index date, if no prior records were
available.
First malignancy diagnosis was obtained by searching clinical
records for Read codes mapping to cancer diagnoses; our
methodology for identifying cancer Read codes and mapping
them to ICD-10 malignancy codes has been previously described
(Bhaskaran et al, 2014). The 21 malignancies that were most
prevalent in the data set were studied (oral (ICD10 code C00–06),
salivary (C07–08), oesophageal (C15), stomach (C16), colorectal
(C18–20), larynx (C32), lung (C34), melanoma (C43), breast
(C50), cervical (C53), uterus (C54–55), ovarian (C56), prostate
(C61), testicular (C62), kidney (C64), bladder (C67), CNS
(C71–72), and thyroid (C73) cancer, and lymphoma (C81–84),
myeloma (C90) and leukaemia (C91–95)). Only the first
malignancy diagnosis was obtained, as determining whether
further malignancy diagnoses were metastases of the first or new
malignancies was infeasible. Participants could therefore only be
considered exposed to one malignancy. A total of 17% of all solid
malignancy diagnoses could not be attributed to any of the 18 most
prevalent site-specific solid malignancies—12% because the Read
code did not specify the site of the cancer, and 5% because they
referred to rarer cancers. In total, 5% of all haematological
malignancies could not be sub-classified further. Non-melanoma
skin malignancies were not considered. As a post hoc analysis,
leukaemia was subdivided into acute, chronic and unspecified/
other. Cancer diagnoses could be dated earlier than the start of
CPRD since we assumed that a previous cancer record would have
been transferred into the CPRD record when the patient registered
with a GP connected to CPRD. However, in case of incomplete
capture of cancer prior to CPRD follow-up, we did a sensitivity
analysis, restricting the study population to those who had no
recorded history of cancer up to 12 months after the start of CPRD
follow-up, and then restricting the time window for defining
cancer exposure to the period after this date. As another sensitivity
analysis, regular use of aciclovir (defined as having at least two
aciclovir prescriptions from a GP o6 weeks apart, any time
between CPRD follow-up start and index date) was adjusted for, to
address potential confounding by such medication.
Statistical methods. The explanatory variables were described by
case–control status.
Association between previous malignancy and zoster risk. Con-
ditional logistic regression was used to estimate the OR with 95%
confidence intervals (CIs) for incident zoster after malignancy
diagnosis. Due to the matching, all analyses accounted for the
matching variables age, sex, practice, and calendar time. The
exposure (prevalent/previous malignancy) was considered at
increasing levels of detail; (1) any malignancy diagnosis, (2) solid
or haematological malignancy, and (3) site-specific solid malig-
nancy or specific haematological malignancy diagnosis. All ORs
represent comparisons to the reference group of those without a
malignancy diagnosis.
The three levels of exposure detail described above were
analysed adjusting for covariates in three stages; (i) adjusting only
for matching factors, (ii) adjusting also for rheumatoid arthritis
(RA), systemic lupus erythematosus (SLE), inflammatory bowel
disease (IBD), COPD, asthma, chronic kidney disease (CKD),
depression, diabetes (by type), HIV, other cellular immunodefi-
ciency (OID), alcohol use, smoking, BMI, and inhaled
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corticosteroid use as these were considered a priori potential
confounders, and (iii) adjusting additionally for haematopoietic
stem cell transplant (HSCT), oral corticosteroid use and other
immunosuppressive therapy prescribed by GPs to explore if the
association was mediated by these. Participants with missing data
on any explanatory variables were excluded from all analyses,
known as a complete case analysis, which is valid if missingness is
independent of the outcome (zoster), conditional on all covariates
(White and Carlin, 2010). Likelihood ratio tests were used to assess
the evidence of an association between exposure and outcome.
Variation by time since cancer diagnosis. For the malignancies
that were associated with zoster in the main analysis, we estimated
the OR of zoster according to time since malignancy diagnosis
(o1, 1–2, 2–3 and 43 years before index date, compared to no
prior malignancy). Only matched factors were adjusted for to avoid
precision loss arising from excluding cases with missing data, and
because our earlier analysis suggested limited confounding;
however, in a sensitivity analysis we adjusted for all potential
confounders as in the main model. The strength of the evidence of
temporal variation in odds of zoster after malignancy diagnosis was
assessed using the likelihood ratio test. A test for linear trend in the
zoster OR with time since malignancy diagnosis was performed by
comparing a model with a binary malignancy variable to a model
that included years since diagnosis. The likelihood value obtained
in a model including only the malignancy as a binary ‘ever vs
never’ malignancy diagnosis was compared to one including
instead a four-level variable describing the time since diagnosis of
that malignancy (1, 2, 3, 43 years) entered as a linear term. This
was done for each of the malignancy types, one at a time. To test
for a non-linear trend, a model with time since malignancy
diagnosis entered as a linear term was compared to one with time
since malignancy diagnosis entered as a categorical term. Again,
these tests were repeated for each specific malignancy.
Variation by age. Interaction between age at index date and
malignancies was assessed by including interaction parameters
between age at index date (o50, 50–60, 60–70, 70–80, and 480
years) and malignancies (solid/haematological), adjusting for all
potential confounders and using likelihood ratio tests to assess the
strength of the evidence of age interaction. This test was performed
by comparing the likelihood of a model including an age-
malignancy interaction variable with one including age and
malignancy entered as independent covariates.
Ethical approval. This study used non-identifiable data routinely
gathered through existing infrastructure (CPRD and HES) within
the health-care system and informed consent for this study was not
needed. The study received ethical approval from the LSHTM
Ethics Committee on the 22 April 2016 (Reference number 11200);
the study was also approved by the CPRD Independent Scientific
Advisory Committee (approval number 16_113A; protocol sup-
plied as Supplementary Appendix B).
RESULTS
A total of 192 081 participants fulfilled the criteria for being
considered incident cases of zoster and had active matched
controls, and 732 035 were identified as controls for these cases
(Figure 1). Table 1 describes the potential confounders and effect
mediators by case–control status. The median age of cases and
controls at index date was similar as expected due to the matching
(62.3 years, interquartile range (IQR) 49.3–73.8 years for cases;
61.8 years, IQR 48.5–73.6 years for controls). The median time
from malignancy diagnosis until zoster was 6.1 years (IQR 2.4 to
12.3 years). The majority of cases (61%) and controls (59%) were
women. Asthma, type 2 diabetes, CKD, COPD, RA, SLE and IBD,
OID, HSCT and HIV were more common among cases than
controls, as was GP prescription of corticosteroids and other
immunosuppressive medications. Supplementary Appendix C
describes the prevalence of malignancy among controls by
covariates.
There were missing data on BMI, smoking and alcohol for a
total of 14% of the participants. Cases less frequently had
any missing data (12%), as did those with malignancies
(10%; Supplementary Appendix D).
Association between previous malignancy and zoster risk.
A total of 192 081 patients had a diagnosis of incident zoster during
follow-up, and 16 219 (8.4%) of these had any type of previous
malignancy diagnosis at the date of zoster diagnosis, as compared
to 48 704 (6.7%) of controls.
Table 2 shows the associations between previous/prevalent
malignancy and incident herpes zoster in models with different
levels of covariate adjustment. There was little change in the
estimated associations between the models accounting for match-
ing factors only (Table 2, ‘Model 1’), and the models adjusting for a
priori potential confounders (Table 2, ‘Model 2’). In the adjusted
models, patients with any previous/prevalent malignancy had 1.29
(95% confidence interval (CI) 1.27–1.32) times higher zoster odds
overall than those without such diagnosis. The OR for the
association between haematological malignancies and zoster was
2.46 (95% CI 2.33–2.60), and 1.19 (95% CI 1.17–1.22) for solid
malignancies.
For 11 of the 18 specific solid (non-haematological) cancers
considered, we found evidence of a positive association with odds
of subsequent zoster in adjusted models (Table 2 ‘Model 2’, and
Figure 2). The largest association was between CNS cancer and
zoster (adjusted OR¼ 2.31, 95% CI 1.85–2.88); followed by lung,
oral and oesophageal cancers (adjusted OR¼ 1.50, (1.33–1.69);
1.41 (1.11–1.79) and 1.41 (1.13–1.76), respectively). More modest
associations were seen for stomach, colorectal, breast, ovarian,
prostate, kidney and bladder cancers (adjusted ORs in the range
1.10 to 1.30). There was little or no evidence that salivary, larynx,
cervix, uterus, testicular, or thyroid cancers, or melanoma were
associated with zoster; though in each case, confidence intervals
did not exclude a small positive association. There was no evidence
that any cancer was inversely associated with zoster. Among the
haematological malignancies, there was strong evidence that
lymphoma, myeloma, and leukaemia were all associated with a
more than doubling in the odds of zoster; myeloma was associated
with the greatest increase in odds (adjusted OR¼ 4.24 (3.60–4.99)).
Adjusting additionally for covariates potentially on the causal
pathway (HSCT, and oral corticosteroid and immunosuppression
prescribed by GPs) resulted in only very slight decreases in most
estimates of exposure OR, at most a 14% decrease for CNS cancer,
from 2.31 to 2.12 (Table 2, ‘Model 3’).
Variation by time since cancer diagnosis. There was good
evidence that the changes in risk of zoster associated with oral,
oesophageal, colorectal, lung, breast, ovarian and kidney cancer,
lymphoma, and myeloma changed according to time since the
cancer diagnosis (Po0.05 in each case), but there was no evidence
that the associations of stomach, prostate, bladder or CNS cancers
or leukaemia with zoster changed over time (Figure 3;
Supplementary Appendix E). For colorectal, lung, and kidney
cancer, lymphoma and myeloma, the associations varied non-
linearly after diagnosis, with peaking zoster OR 1–3 years after
malignancy diagnosis; for oral, oesophageal, ovarian and breast
cancer, there was no evidence that the association was non-linear
(P for departure from linearity40.05), with zoster odds generally
decreasing with time since diagnosis. Adjusting for potential
confounders did not change the estimates substantially
(Supplementary Appendix E).
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Variation by age. There was strong evidence of interaction
between age at index date and malignancy (Po0.001; Figure 4,
Supplementary Appendix F), with malignancies more strongly
associated with zoster among younger participants (for solid
malignancies OR¼ 1.70 (1.54–1.86) among those o50 vs 1.11
(1.06–1.16) among those 480 years old, and 3.08 (2.55–3.72) vs
1.77 (1.55–2.03) for haematological).
Restricting the data set to before zoster vaccination commenced
in September 2013 did not affect the results importantly, but
restricting the data set to those without a malignancy diagnosis
until after 12 months of follow-up in CPRD led to generally
increasing strength of association (Supplementary Appendix G).
Aciclovir was prescribed regularly by a GP among 0.5% of zoster
cases and 0.2% of controls, but there were no important changes in
estimated associations between cancer and zoster when such
prescription was adjusted for (Supplementary Appendix G). Acute
and chronic leukaemia were both similarly associated with zoster,
and there was no evidence of difference in the timing of excess
zoster risk after a diagnosis of either of them (P¼ 0.97 and 0.89,
respectively, Supplementary Appendix H).
DISCUSSION
Key results. Having a previous cancer diagnosis was associated
with a modest, but clear increase in the odds of zoster, but there
was substantial heterogeneity in the association according to type
of malignancy. The largest associations were observed between
haematological malignancies and subsequent odds of zoster, with
lymphoma and leukaemia associated with a more than doubling in
the odds of zoster in adjusted models, and myeloma associated
with a 4.24-fold increase in odds. 11 out of 18 of the solid (non-
haematological) cancers investigated were also positively associated
with subsequent zoster risk; the largest association was with CNS
cancer (adjusted OR¼ 2.31), while oral, oesophageal, stomach,
colorectal, lung, breast, ovarian, prostate, kidney, and bladder
cancers were also each associated with 10–50% increases in odds of
zoster. This association between cancer and zoster was larger
among younger patients, and for several malignancies the
association varied by time since diagnosis, typically peaking within
3 years after malignancy diagnosis.
Strengths and limitations. To our knowledge, this is the largest
study to date to look in comparable detail at the associations
between a wide range of cancer types and subsequent zoster risk.
The large study size enabled us to estimate associations with high
precision, even for less common cancer types, which is a major
strength of this study. However, the use of routinely collected data
that enabled this large study size inevitably led to some limitations.
CPRD generally has high validity (Herrett et al, 2010), but no
known study has validated CPRD zoster diagnosis specifically. Our
outcome was not based on standardised diagnostic criteria, which
is a limitation, and there is no information available on how each
zoster diagnosis was made, but in clinical practice in the UK, zoster
is usually diagnosed based on observing a characteristic unilateral
rash with dermatomal distribution rather than laboratory testing
(Forbes et al, 2014), as per recent guidelines (Werner et al, 2017).
Outside CPRD, two studies have compared clinical zoster
diagnosis to serological (Opstelten et al, 2007) and PCR (Tseng
et al, 2013) verified diagnosis and found a positive predictive value
(PPV) of 91% and 85%, respectively. Four studies (Donahue et al,
1995; Heymann et al, 2008; Yawn et al, 2011; Habel et al, 2013)
estimated the PPV of electronic database zoster diagnosis by
comparing findings to review of patient records, reporting PPVs
between 69 and 87%. Two studies using either questionnaire or
PHN diagnosis estimated that 95 (Lu et al, 2009) and 81%
(Weitzman et al, 2013) of patients respectively sought health care
for zoster. The extent of incorrect rejection of herpes zoster
diagnosis in primary care has, to our knowledge, not been studied,
but there are only a few rare clinical conditions with which the
characteristic clinical appearances could be confused. The most
common potential misdiagnosis is herpes simplex, but this only
rarely presents with a similar, dermatomal distribution (Rubben
et al, 1997). Considering that zoster is usually easy to diagnose
clinically, the proportion of zoster cases or controls that are
misclassified is likely to be small. There is no clear reason why
malignancy would cause a clinician to be more or less likely to
diagnose a zoster-like rash as zoster, so any misclassification is
likely to be non-differential, thereby biasing the results towards
UK General population 2000–2015
98% registered with GP
7% participating in CPRD
192 166 participants fulfilling
criteria for incident zoster, i.e.
included as cases
85 excluded as
lacking active
controls
32 952 excluded
as considered
inactive
192 081 cases
23 994 cases with
missing data
168 087 cases in complete-
records analysis
732 035 controls
164 483 controls
with missing data or
matched case with
missing data
567 552 controls in complete-
records analysis
764 987 participants fulfilling
matching criteria, i.e.
included as controls
Figure 1. Participant flow chart.
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null (Forbes et al, 2014). Studies using cases confirmed through
patient record review (Hata et al, 2011; Habel et al, 2013), found
stronger associations with malignancies, but these estimates may
be biased upwards if the record reviewers were not (reportedly)
blind to exposure status.
Validity of CPRD cancer recording has been investigated via
concordance with national registration and hospital data;490% of
CPRD cancers were confirmed in other data sources, and490% of
nationally registered cancers were present in CPRD, with CPRD
missing mainly rapidly fatal malignancies (Boggon et al, 2013).
Missing such cancers would be expected to lead to a bias towards
the null, but such cases are likely to be rare, so this should not have
had a major impact on our results. Twelve per cent of cancers were
of unspecified site, these may have included metastatic cancers
with unknown primaries, or cancers with imperfect coding of
cancer site (e.g., site details may have been recorded in non-coded
free text). As patients with these ‘other/unclear solid’ malignancies
may have had more advanced cancer at diagnosis, they may have
been generally sicker and at higher zoster risk, causing bias towards
null in the associations with specific malignancies that are
consequently misclassified. However, the OR for ‘other/unclear
solid malignancy’ was virtually identical to that for ‘any solid
malignancy’ suggesting that any such bias is likely to have been of
small magnitude.
The magnitude of association increased in a sensitivity analysis
that excluded those with a prevalent malignancy diagnosis at start
of CPRD follow-up (defined as any diagnosis recorded before 12
months of complete follow-up in CPRD). This change would be
consistent with incomplete capture of pre-follow-up (i.e., histor-
ical) malignancy diagnosis in the primary analysis, leading to a bias
towards the null. However, the estimated associations were
qualitatively similar and the changes in estimates were modest
Table 1. Distribution of covariates by case–control status
Controls Cases
N % N %
Total number 732 035 192 081
Matching factors
Gender
Male 286 486 39.1 78 011 40.6
Female 445 549 60.9 114 070 59.4
Age group
18–29 52190 7.1 14 517 7.6
30–49 138077 18.9 37 554 19.6
50–59 137975 18.8 36 310 18.9
60–69 162446 22.2 41 540 21.6
70–79 147765 20.2 37 547 19.5
80–89 82390 11.3 21 182 11.0
90þ 11192 1.5 3431 1.8
Adjusted for in step 2 (comorbidities and lifestyle factors)
Systemic lupus erythematosus 1139 0.2 537 0.3
Inflammatory bowel disease 7319 1.0 2589 1.3
Reumatoid arthritis 9689 1.3 3845 2.0
Chronic obstructive pulmonary disease 28 958 4.0 9683 5.0
Depression 29 136 4.0 8980 4.7
Asthma 37004 5.1 11 673 6.1
Chronic kidney disease 48 959 6.7 14 358 7.5
HIV 159 0.0 189 0.1
Other cellular immunodeficiency 298 0.0 140 0.1
Inhaled corticosteroid therapy 46 013 6.3 15 172 7.9
Diabetes
Type 1 1374 0.2 457 0.2
Type 2 55492 7.6 14 974 7.8
Unknown 3011 0.4 1032 0.5
BMI category
Underweight 14 263 1.9 3739 1.9
Normal weight 250 052 34.2 66 339 34.5
Overweight 240 445 32.8 64 464 33.6
Obese 155263 21.2 41 659 21.7
Missing 72012 9.8 15 880 8.3
Smoking
Never-smoker 277 413 37.9 72 419 37.7
Current smoker 173 609 23.7 43 288 22.5
Ex-smoker 267 778 36.6 74 701 38.9
Missing 13235 1.8 1673 0.9
Alcohol
Never-drinker 72 345 9.9 18 147 9.4
Current drinker 515 761 70.5 137 716 71.7
Ex-drinker 68 986 9.4 19 161 10.0
Missing 74943 10.2 17 057 8.9
Adjusted for in step 3 (potential cancer treatment)
Other immunosuppressive treatmenta 5075 0.7 2845 1.5
Oral corticosteroid treatmenta 17189 2.3 7901 4.1
Haematopoietic stem cell transplant 29 0.0 54 0.0
Abbreviation: BMI¼body mass index. Note. Patients may have many comorbidities and treatments.
aOther classifications than those used in original publication (Forbes et al, 2014), and these labels are mixed up in this publication.
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compared to the main analysis, suggesting that this information
bias had only limited impact.
More health-care contact among patients with a prior cancer
diagnosis could have led to a greater opportunity to diagnose zoster
early. Patients with malignancies had a similar mean consultation
rate as those with epilepsy (18.4 vs 19.6 consultations per year), for
whom only a very small increase in odds of zoster has been found
(OR¼ 1.05, 99% CI 0.97–1.14; Forbes et al, 2014), indicating that if
there is ascertainment bias due greater GP consultation, this is
likely to have had only limited impact. Controls were required to
have recent GP contact, which may have disproportionally
excluded healthy controls and introduced bias towards null
(Forbes et al, 2014). However, only 5% of controls were excluded
due to inactivity, so the magnitude is likely small.
There were some missing data in lifestyle-related variables (BMI,
smoking, alcohol); these were considered unlikely to be missing at
random in a primary care setting (Bhaskaran and Smeeth, 2014), so
we used a complete case analysis. Having missing data was inversely
related to the outcome in unadjusted analysis but the assumption
underlying complete case analysis, which relates to conditional
independence between missingness and outcome, cannot be tested
in the observed data due to the need to condition on the missing
values themselves. Matched sets with missing data among cases are
excluded, so that the consequences for analysis of missing data
among cases is larger than among controls, likely creating bias away
from zero as those with missing data were generally healthier. As
only 14% of individuals overall had missing data this is unlikely to
completely explain the observed associations.
Some potential confounders, such as ethnicity/race/country of
origin and reproductive history were unavailable, but the a priori
importance of these was considered quite limited. The covariates
considered on the causal pathway (GP prescribed corticosteroids and
other immunosuppressive drugs, adjusted for in ‘Model 3’) may have
inadequately captured use of these drugs by cancer patients, who
would more likely receive such treatments as part of hospital
prescribing, which we could not measure; this may explain the
minimal change in estimates when adjusting for these variables,
limiting our ability to conclude definitively that receipt of these
treatments did not mediate some of the associations seen. In addition
to lacking information on surgery and chemo- and radiotherapy,
information on antiviral prophylaxis is likely to be incomplete, as
these treatments are delivered in secondary/tertiary care. Our
sensitivity analysis on aciclovir use might therefore not truly capture
confounding by use of this medication. Information on cancer stage
could have been used as a proxy for what type of treatment a patient
was receiving and thereby the extent of immunosuppression, but
such information was unfortunately unavailable.
Interpretation. These results strengthen the evidence that malig-
nancies are associated with a higher zoster risk, congruent with
previous studies (Figure 2; Heymann et al, 2008; Hata et al, 2011;
Habel et al, 2013; Weitzman et al, 2013; Forbes et al, 2014; Liu et al,
2015; Yenikomshian et al, 2015). The discrepancies with estimates
for haematological malignancies obtained using largely the same
cohort previously (Forbes et al, 2014; Supplementary Appendix I),
is likely attributable to the previous study using diagnoses within
two years and less specific myeloma Read codes, for example,
monoclonal gammopathy was coded as myeloma in this study,
whereas the present study used only Read codes considered to be
more definitely indicating myeloma.
Two broad potential mechanisms may explain an association
between prevalent/previous malignancy and zoster. First, they may
Table 2. Prevalence of malignancies among cases and controls, and association between prevalent/previous malignancy and
incident zoster
Controls Cases Model 1a Model 2b Model 3c
Malignancy type N (%) N (%)
OR (with
95% CI)
P
OR (with
95% CI)
P
OR (with
95% CI)
P
No malignancy 683331 (93.3) 175952 (91.6) 1 ( ) 1 ( ) 1 ( )
Malignancy (C00–43þ 45–96) 48704 (6.7) 16129 (8.4) 1.30 (1.27–1.33) o0.001 1.29 (1.27–1.32) o0.001 1.29 (1.27–1.32) o0.001
Any solid (C00–43þ45–80) 44979 (6.1) 13736 (7.2) 1.20 (1.18–1.23) o0.001 1.19 (1.17–1.22) o0.001 1.19 (1.16–1.22) o0.001
Oral (C00–06) 298 (0) 102 (0.1) 1.41 (1.11–1.78) 0.007 1.41 (1.11–1.79) 0.006 1.40 (1.10–1.78) 0.007
Salivary (C07–08) 271 (0) 79 (0) 1.18 (0.91–1.55) 0.22 1.17 (0.89–1.53) 0.26 1.17 (0.89–1.53) 0.26
Oesophageal (C15) 359 (0) 131 (0.1) 1.42 (1.14–1.77) 0.002 1.41 (1.13–1.76) 0.003 1.39 (1.11–1.73) 0.005
Stomach (C16) 311 (0) 103 (0.1) 1.28 (1.00–1.62) 0.051 1.30 (1.02–1.66) 0.035 1.30 (1.02–1.65) 0.042
Colorectal (C18–20) 4805 (0.7) 1375 (0.7) 1.10 (1.03–1.18) 0.003 1.10 (1.03–1.17) 0.005 1.10 (1.03–1.18) 0.005
Larynx (C32) 318 (0) 75 (0) 0.89 (0.68–1.17) 0.41 0.87 (0.66–1.14) 0.3 0.86 (0.65–1.13) 0.28
Lung (C34) 1047 (0.1) 437 (0.2) 1.62 (1.44–1.83) o0.001 1.50 (1.33–1.69) o0.001 1.44 (1.27–1.62) o0.001
Melanoma (C43) 2965 (0.4) 818 (0.4) 1.07 (0.98–1.16) 0.14 1.07 (0.98–1.16) 0.12 1.07 (0.99–1.17) 0.1
Breast (C50) 13520 (1.8) 4205 (2.2) 1.24 (1.20–1.29) o0.001 1.24 (1.20–1.29) o0.001 1.24 (1.20–1.29) o0.001
Cervical (C53) 900 (0.1) 243 (0.1) 1.10 (0.95–1.29) 0.2 1.10 (0.95–1.28) 0.22 1.09 (0.94–1.27) 0.25
Uterus (C54–55) 1299 (0.2) 312 (0.2) 0.95 (0.83–1.08) 0.42 0.95 (0.83–1.09) 0.47 0.96 (0.84–1.09) 0.51
Ovarian (C56) 974 (0.1) 298 (0.2) 1.16 (1.01–1.34) 0.038 1.17 (1.01–1.34) 0.037 1.17 (1.01–1.35) 0.034
Prostate (C61) 5812 (0.8) 1690 (0.9) 1.15 (1.08–1.22) o0.001 1.14 (1.08–1.21) o0.001 1.13 (1.07–1.20) o0.001
Testicular (C62) 385 (0.1) 127 (0.1) 1.16 (0.93–1.45) 0.19 1.16 (0.93–1.44) 0.2 1.15 (0.92–1.43) 0.22
Kidney (C64) 407 (0.1) 139 (0.1) 1.34 (1.09–1.64) 0.006 1.28 (1.05–1.57) 0.019 1.26 (1.03–1.55) 0.028
Bladder (C67) 2151 (0.3) 679 (0.4) 1.26 (1.15–1.38) o0.001 1.24 (1.13–1.36) o0.001 1.25 (1.14–1.37) o0.001
CNS (C71–72) 248 (0) 159 (0.1) 2.28 (1.83–2.84) o0.001 2.31 (1.85–2.88) o0.001 2.12 (1.70–2.65) o0.001
Thyroid (C73) 362 (0) 105 (0.1) 1.15 (0.92–1.45) 0.22 1.14 (0.91–1.43) 0.26 1.12 (0.89–1.41) 0.33
Other/unclear solid 8547 (1.2) 2659 (1.4) 1.22 (1.17–1.28) o0.001 1.21 (1.15–1.27) o0.001 1.20 (1.14–1.26) o0.001
Any haematological (C81–96) 3725 (0.5) 2393 (1.2) 2.49 (2.35–2.64) o0.001 2.46 (2.33–2.60) o0.001 2.42 (2.28–2.56) o0.001
Lymphoma (C81–86) 1979 (0.3) 1213 (0.6) 2.35 (2.17–2.54) o0.001 2.32 (2.14–2.51) o0.001 2.28 (2.11–2.47) o0.001
Myeloma (C90) 356 (0) 367 (0.2) 4.27 (3.63–5.02) o0.001 4.24 (3.60–4.99) o0.001 4.05 (3.43–4.77) o0.001
Leukaemia (C91–95) 1198 (0.2) 713 (0.4) 2.34 (2.11–2.59) o0.001 2.31 (2.09–2.56) o0.001 2.29 (2.07–2.54) o0.001
Other haematological (C96/88) 192 (0) 100 (0.1) 1.83 (1.40–2.38) o0.001 1.78 (1.36–2.32) o0.001 1.75 (1.34–2.29) o0.001
aadjusted for matching factors only, that is, age, sex, practice and calendar time.
badjusted additionally for diabetes, SLE, IBD, RA, COPD, depression, asthma, renal failure, HIV, OID, inhaled corticosteroid treatment, BMI, smoking and alcohol use.
cAdjusted additionally for covariates potentially on the causal pathway that is, GP prescribed oral corticosteroids and other immunosuppression, and HSCT. See Supplementary Appendix B for
estimates of the other covariates.
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share the underlying cause of immunodysfunction, as both
malignancies and zoster are favoured by a weakened immune
system (Cotton et al, 2013); second, the malignant disease and/or
its treatment may cause immune system dysfunction, causing
zoster (Cotton et al, 2013; Habel et al, 2013). This study cannot
differentiate between these mechanisms as information on immune
system function and malignancy treatment is lacking. Haemato-
logical malignancies lead to severe immunosuppression from
disease and its treatment, and are those with the strongest link to
zoster, while malignancies such as melanoma, which is not treated
with immunosuppressive therapy, are not as strongly associated
with zoster, supporting the role of systemic chemotherapy. That
CNS cancer patients have such comparatively high odds of zoster
has, to our knowledge, not been described with such precision and
adequate methodology previously. Plausibly, immune dysfunction
specifically within the nervous system might increase the risk of
both zoster and CNS cancer, or the treatment of CNS cancer might
lead to a high risk of zoster, for example, through high-dose
corticosteroids for decreasing oedema around intracranial
tumours, chemotherapy able to cross the blood-brain barrier, or
radiotherapy triggering zoster reactivation from cranial nerve
nuclei.
Some studies considering history of zoster as a risk factor for
malignancies (i.e., the opposite temporality) have found positive
associations (Cotton et al, 2013) suggesting that the common-cause
hypothesis is one valid explanation. The temporal variation of
zoster odds after diagnosis indicates that something about the
malignancy, rather than only a common cause (immunodeficiency)
leads to an increased zoster risk, as immunodeficiency might be
expected to be constant or deteriorate with time/age rather than
recover spontaneously. For most malignancies, zoster odds ratio
decreased with time, perhaps as an increasing proportion of
surviving patients become cancer-free and are no longer being
treated with potent immunosuppression. This finding also
indicates that zoster vaccination of cancer patients might be most
beneficial quite soon after diagnosis, if safety and effectiveness can
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Figure 2. Odds ratios of zoster for different malignancy diagnoses adjusted for potential confounders, compared to previous studies. Black filled
circles—present study estimates. Previous studies in grey: Filled triangle—(Liu et al, 2015), square—(Yenikomshian et al, 2015), hollow triangle—
(Habel et al, 2013) hollow circle—(Heymann et al, 2008), diamond—(Forbes et al, 2014).
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be confirmed in this setting. The current, live zoster vaccine is
contraindicated among the profoundly immunosuppressed, but
efforts are underway to develop a subunit vaccine that could be
useful among these patients. One previous study found a
constantly increased zoster rate after malignancy diagnosis
(Yenikomshian et al, 2015), whereas another found a pattern
similar to our study (Weitzman et al, 2013).
The decreasing malignancy-zoster association with increased
age may be due to absence of other zoster risk factors and/or more
aggressive chemotherapy (Yenikomshian et al, 2015) among the
young. These findings are consistent with previous studies
(Heymann et al, 2008; Habel et al, 2013).
Generalisability. As the study population is broadly representative
of a high-income country, and the findings are congruent with
studies from similar settings, the findings are likely to be
generalisable to high-income countries. However, changes in cancer
treatments, and the increasing popularity of immune-modulating
cancer therapies mean that the associations we have observed
between some cancers and zoster risk may change in the future.
Recommendations. A recent diagnosis of cancer raises the index
of clinical suspicion of zoster among patients presenting with
characteristic initial symptoms. Such patients may benefit from
rapid initiation of antiviral therapy, to reduce acute pain and
complications, although strong evidence is lacking for a protective
effect against PHN. Future studies should evaluate the safety,
timing and cost-benefit balance for vaccinating cancer patients
against zoster, considering each specific malignancy separately. To
obtain maximum benefit, vaccination as soon as possible after
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Figure 3. Zoster odds ratio by time since malignancy diagnoses. Numerical results are available in Supplementary Appendix E. Note: panels have
different y-scales.
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Figure 4. Age-stratum specific odds ratios of herpes zoster among malignancy patients. Numerical results are available in Supplementary
Appendix F.
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cancer diagnosis may be needed, prior to immunosuppressive
therapies being initiated. New vaccines, which are currently under
development, may be available for immunosuppressed patients in
the future. A previous study using CPRD found that, among
patients with herpes zoster, those with a history of cancer have a
similar risk of developing postherpetic neuralgia as other patients
with no history of cancer (Forbes et al, 2016).
Future research should analyse zoster risk in relation to cancer
therapy, malignancy stage and other detailed clinical information,
to better understand the mechanisms explaining the association
between cancer and zoster and how the excess risk may be
prevented.
CONCLUSIONS
Patients with malignancies are at increased zoster risk, with quite
marked variation by type of cancer, possibly attributable to
different treatment patterns. Risks were higher in the first few years
post cancer diagnosis, and among younger people.
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